The impact of clinical and genetic factors on ticagrelor and clopidogrel antiplatelet therapy [0.03%]
临床和遗传因素对替格瑞洛和氯吡格雷抗血小板治疗的影响
Vacis Tatarunas,Nora Kupstyte,Remigijus Zaliunas et al.
Vacis Tatarunas et al.
Aim: To determine clinically significant factors which may alter the effect of dual antiplatelet therapy with aspirin and ticagrelor or clopidogrel in patients who had undergone percutaneous coronary intervention and sten...
Pharmacogenomics in Asia: a systematic review on current trends and novel discoveries [0.03%]
亚洲的药物基因组学：当前趋势和新发现的系统评价
Hazel Xiaohui Ang,Sze Ling Chan,Levana L Sani et al.
Hazel Xiaohui Ang et al.
While early pharmacogenomic studies have primarily been carried out in Western populations, there has been a notable increase in the number of Asian studies over the past decade. We systematically reviewed all pharmacogenomic studies conduc...
Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach [0.03%]
药理基因组学方法对减少严重药物所致皮肤不良反应的建议修订
Wei Chuen Tan-Koi,Cynthia Sung,Yong Yeow Chong et al.
Wei Chuen Tan-Koi et al.
The Health Sciences Authority launched a pharmacogenetics initiative in 2008 to facilitate evaluation of pharmacogenetics associations pertinent for Chinese, Malays and Indians in Singapore. The aim was to reduce the incidence and unpredict...
Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics [0.03%]
维生素D途径基因多态性对利福平血浆和细胞内药动学的作用
Sarah Allegra,Giovanna Fatiguso,Andrea Calcagno et al.
Sarah Allegra et al.
Aim: We retrospectively evaluate the pharmacogenetic role of single nucleotide polymorphisms involved in rifampicin transport (SLCO1B1, MDR1 and PXR genes) and vitamin D (VDR, CYP24A1 and CYP27B1 genes) metabolism and act...
Christophe Le Tourneau,Maud Kamal,Ivan Bièche
Christophe Le Tourneau
Availability of CYP2D6 genotyping results in general practitioner and community pharmacy medical records [0.03%]
在全科医生和社区药房医疗记录中提供CYP2D6基因分型结果的可用性
Mirjam Simoons,Hans Mulder,Robert A Schoevers et al.
Mirjam Simoons et al.
Aim: To investigate the availability of CYP450-2D6 (CYP2D6) genotyping results in general practitioner (GP) and/or community pharmacy records, and the influence thereof on psychotropic CYP2D6 substrate dosing. ...
Rapid and reliable screening of HLA-B*15:02 in four Chinese populations using single-tube multiplex real-time PCR assay [0.03%]
在中国四个群体中采用单管多重实时PCR方法快速准确筛查HLA-B*15：02等位基因
Huijuan Wang,Xing Kang,Shaohe Zhou et al.
Huijuan Wang et al.
Aim: HLA-B*15:02 screening should be performed to prevent antiepileptic drug induced severe cutaneous adverse reactions in populations of Asian origin. This study aimed to develop fast and reliable HLA-B*15:02 genotyping...
Clinical and educational impact of pharmacogenomics testing: a case series from the INGENIOUS trial [0.03%]
药物基因分型检测的临床和教育影响：INGENIOUS试验中的病例系列分析
Rebecca C Pierson,Brandon T Gufford,Zeruesenay Desta et al.
Rebecca C Pierson et al.
Pharmacogenomic testing has become increasingly widespread. However, there remains a need to bridge the gap between test results and providers lacking the expertise required to interpret these results. The Indiana Genomics Implementation tr...
Clinical Trial
Pharmacogenomics. 2017 Jun;18(9):835-841. DOI:10.2217/pgs-2017-0042 2017
Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate [0.03%]
药理学因素对吉西他滨活性代谢产物吉西他滨三磷酸累积的影响
Ivana Rizzuto,Essam Ghazaly,Godefridus J Peters
Ivana Rizzuto
Gemcitabine is an anticancer agent acting against several solid tumors. It requires nucleoside transporters for cellular uptake and deoxycytidine kinase for activation into active gemcitabine-triphosphate, which is incorporated into the DNA...
Marzia Del Re,Eleonora Rofi,Valentina Citi et al.
Marzia Del Re et al.
Letter in regards to: Del Re M, Rofi E, Citi V, Fidilio L, Danesi R. Should CYP2D6 be genotyped when treating with tamoxifen? Pharmacogenomics 17(18), 1967-1969 (2016). In response to: Damkier P. Don't think twice it's all right: tamoxifen ...